In-depth guide

UPDATED FEB 2026

Hair Relaxer Settlement Amounts

Part of the Hair Relaxer Cancer investigation

The short answer

No hair relaxer cases have settled or gone to trial yet. Attorney estimates project $90,000–$1,000,000+ depending on injury type and severity.

Bellwether trials expected in 2027 will establish actual case values.

People's Justice Research TeamUpdated February 20, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

Free · Confidential · About 2 minutes · A case specialist responds within 1 business day

Your answers are never sold or shared without your consent.

Current Settlement Status

As of February 2026, no hair relaxer cases have settled or gone to trial. The MDL is in pre-trial discovery and expert preparation. Daubert hearings on general causation are scheduled for April–June 2026, with bellwether trials expected in mid-2027. Settlement negotiations typically begin in earnest after bellwether outcomes establish value ranges.

Projected Settlement Tiers

Attorney estimates based on comparable mass tort outcomes: Tier 1 (uterine fibroids with hysterectomy): $90,000–$150,000; Tier 2 (uterine/endometrial cancer): $200,000–$750,000; Tier 3 (ovarian cancer or young-adult uterine cancer): $300,000–$1,000,000+. Younger victims and more severe cancer diagnoses command higher values.

Comparable Mass Tort Benchmarks

The talcum powder ovarian cancer litigation ($6.5B for ~60,000 claimants = ~$108K average) and Roundup cancer litigation ($10.9B for ~66,000 claimants = ~$165K average) provide relevant benchmarks. Individual bellwether verdicts in those cases reached much higher amounts.

When to Expect Resolution

Late 2027 at the earliest for global settlement. Filing now is critical — the statute of limitations is running, and being in the MDL pipeline when settlement programs are established ensures your case is included.

Key data

Data & Statistics

3 SOURCED FIGURES

14,700+

Total cases filed in MDL 3060

5,230

Cancer cases eligible for bellwether selection

2027

Expected first bellwether trials

Research & evidence

Scientific Evidence

Hair Relaxer Use and Risk of Uterine Cancer in the Black Women's Health Study

Bertrand KA, Coogan PF, Palmer JR (2023). Environmental Research

View on PubMed

Use of Straighteners and Other Hair Products and Incident Uterine Cancer

Chang CJ, O'Brien KM, Keil AP, Gaston SA, Jackson CL, Sandler DP, White AJ (2022). Journal of the National Cancer Institute

View on PubMed

Use of Hair Products in Relation to Ovarian Cancer Risk

White AJ, Sandler DP, et al. (2021). Carcinogenesis

View on PubMed

FAQ

Frequently Asked Questions

36 QUESTIONS

Chemical hair relaxers contain endocrine-disrupting chemicals (EDCs) — phthalates, parabens, formaldehyde, BPA, and cyclosiloxanes — that mimic estrogen when absorbed through the scalp. Chronic estrogen overstimulation promotes abnormal growth in hormone-sensitive tissues. The NIH Sister Study found that frequent relaxer users face a 155% increased risk of uterine cancer and a 119% increased risk of ovarian cancer.

Dive deeper

Related Guides

7 GUIDES

The full investigation

Part of the Hair Relaxer Cancer Investigation